Walter Nahm is a Dermatology physician affiliated with University of California San Diego. OpenAlex indexes 43 publications with 1,233 citations (h-index 15); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
7695 Cardinal Court
Suite 200
San Diego, CA 921233305
Telephone
858-278-8835Provider last certified this registry record 20 Jul 2021.
Clinical trials
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
10 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- LEO Pharma Inc.Program year202511 payments
- VERTEX PHARMACEUTICALS INCORPORATEDProgram year20252 payments
- Integra LifeSciences CorporationProgram year20242 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
32.3%Corticosteroid28.5%Triamcinolone acetonide78%Triamcinolone Acetonide20%Methylprednisolone2%Part D + Part B≥94 patientsAllylamine Antifungal1.4%Terbinafine Hcl100%Part D≥21 patients+ 2 more classes in this area
Anti-infectives
21.4%Nitroimidazole Antimicrobial10.6%Metronidazole100%Part D≥138 patientsTetracycline-class Drug5.3%Doxycycline Monohydrate100%Part D≥76 patients+ 3 more classes in this area
Genitourinary & hormones
13.9%Other antiinfectives and antiseptics11.8%Ciclopirox100%Part D≥182 patients5-alpha Reductase Inhibitor2.1%Dutasteride100%Part D≥15 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open‐label extension study
Journal of the European Academy of Dermatology and Venereology
2025 - Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial
Journal of the American Academy of Dermatology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Jay Giedd, MD
University of California San Diego
Robert Weinreb, MD
University of California San Diego
Dilip Jeste, MD
University of California San Diego
Igor Grant, MD
University of California San Diego
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”